Journal article
Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia
N Scott, DM Iser, AJ Thompson, JS Doyle, ME Hellard
Journal of Gastroenterology and Hepatology Australia | Published : 2016
DOI: 10.1111/jgh.13223
Abstract
Background and Aim:: Reducing the burden of hepatitis C virus (HCV) related liver disease will require treating people who inject drugs (PWID), the group at most risk of infection and transmission. We determine the cost-effectiveness of treating PWID with interferon-free direct-acting antiviral therapy in Australia. Methods:: Using a deterministic model of HCV treatment and liver disease progression, including a fixed rate of re-infection, the expected healthcare costs and quality-adjusted life years (QALYs) of a cohort of newly HCV-infected PWID were calculated for: no treatment; treatment after initial infection ("early-treatment"); and treatment prior to developing compensated cirrhosis (..
View full abstractGrants
Funding Acknowledgements
The authors gratefully acknowledge the contribution to this work through project funding from the Victorian Infectious Diseases Service Special Purpose Fund at Melbourne Health, and support to the Burnet Institute provided by the Victorian Government Operational Infrastructure Support Program. NS is the recipient of a Burnet Institute Jim and Margaret Beever fellowship; MH, JD, and AT are the recipients of National Health and Medical Research Council fellowships.